Canada markets open in 4 hours 42 minutes

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
44.40+0.20 (+0.45%)
As of 08:01AM CET. Market open.
Full screen
Previous Close44.20
Open44.40
Bid44.40 x N/A
Ask44.80 x N/A
Day's Range44.40 - 44.40
52 Week Range7.40 - 44.60
Volume4
Avg. Volume59
Market Cap2.078B
Beta (5Y Monthly)-0.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

    SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the following investor conferences this month: Jefferies London Healthcare Conference: Fireside chat on Thursday, November 17 at 8:00 a.m. GMT (3:00 a.m. ET) in London, England.EvercoreISI HealthCONx Conf

  • GlobeNewswire

    Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022

    Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD categorySOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, announced it will present late-breaking oral and poster presentations on its lead product candidate efruxifermin (EFX) today at the Am

  • GlobeNewswire

    Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2022 and provided business updates. "Our recently reported Week 24 results from the Phase 2b HARMONY study in patients with pre-cirrhotic NASH (F2-F3) contribute to the